Loading...
Please wait, while we are loading the content...
Similar Documents
A Nomogram-Based Prognostic Model for Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib: A Multicenter Study
| Content Provider | MDPI |
|---|---|
| Author | Marasco, Giovanni Poggioli, Francesco Colecchia, Antonio Cabibbo, Giuseppe Pelizzaro, Filippo Giannini, Edoardo Marinelli, Sara Rapaccini, Gian Caturelli, Eugenio Marco, Mariella Di Biasini, Elisabetta Marra, Fabio Morisco, Filomena Foschi, Francesco Zoli, Marco Gasbarrini, Antonio Baroni, Gianluca Svegliati Masotto, Alberto Sacco, Rodolfo Raimondo, Giovanni Azzaroli, Francesco Mega, Andrea Vidili, Gianpaolo Brunetto, Maurizia Nardone, Gerardo Alemanni, Luigina Dajti, Elton Ravaioli, Federico Festi, Davide Trevisani, Franco Group, Italian Liver Cancer (I T. A. LI.CA.) |
| Copyright Year | 2021 |
| Description | Among scores and staging systems used for HCC, none showed a good prognostic ability in patients with advanced HCC treated with Sorafenib. We aimed to evaluate predictive factors of overall survival (OS) and drug response in HCC patients undergoing Sorafenib included in the Italian Liver Cancer (ITA.LI.CA.) multicenter cohort. Patients in the ITA.LI.CA database treated with Sorafenib and updated on 30 June 2019 were included. Demographic and clinical data before starting Sorafenib treatment were considered. For the evaluation of predictive factors for OS, a time-dependent Cox proportional hazard model was used. A total of 1107 patients were included in our analysis. The mean age was 64.3 years and 81.7% were male. Most patients were staged as BCLC B (205, 18.9%) or C (706, 65.1%). The median time of Sorafenib administration was 4 months (interquartile range (IQR) 2–12), and the median OS was 10 months (IQR: 4–20). A total of 263 patients (33.8%) out of 780 with available evaluation experienced objective tumoral response to Sorafenib. The Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) (hazard ratio (HR) 1.284), maximum tumoral diameter (HR 1.100), plasma total bilirubin (HR 1.119), aspartate amino transferase assessed as multiple of the upper normal value (HR 1.032), alpha-fetoprotein ≥200 ng/mL (HR 1.342), hemoglobin (HR 0.903) and platelet count (HR 1.002) were associated with OS at multivariate Cox regression analysis. Drug response was predicted by maximum tumoral diameter and platelet count. A novel prognostic nomogram for patients undergoing Sorafenib is hereby proposed. The novelty introduced is the comprehensive patient’s assessment using common markers of patient’s general status, liver damage and function and HCC biology. Further studies are required to test its accuracy and provide external validation. |
| Starting Page | 2677 |
| e-ISSN | 20726694 |
| DOI | 10.3390/cancers13112677 |
| Journal | Cancers |
| Issue Number | 11 |
| Volume Number | 13 |
| Language | English |
| Publisher | MDPI |
| Publisher Date | 2021-05-29 |
| Access Restriction | Open |
| Subject Keyword | Cancers Oncology Sorafenib Hepatocellular Carcinoma Survival Prognosis Cohort Study |
| Content Type | Text |
| Resource Type | Article |
